OTC Pharmaceuticals in Poland

OTC Pharmaceuticals in Poland industry profile provides top-line qualitative and quantitative summary information including: market size (value 2009-13, and forecast to 2018). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Poland otc pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

The OTC pharmaceuticals market consists of the retail sale of traditional medicines, cough and cold preparations (tablets, mixtures, lozenges, topical remedies, inhalers), vitamins and minerals (multi-vitamins, single minerals, single vitamins, tonics, cod liver oil), indigestion preparations (tablets, powders, mixtures), analgesics (Paracetamol, Ibuprofen, Aspirin and other analgesics), and medicated skin products (anti-bacterials, acne treatments, anti-fungal, disinfectants and other), topical OTC medicines (anesthetic products, anti-itch products, antibiotic creams/gels), plasters & bandages (adhesive bandages/plasters, first aid tape, gauze pads/rolled gauze, liquid bandages and other tape or bandage), first aid kits and other (anti-smoking aids, rectal medications, eye/ear drops, sleeping aids, and motion sickness). The market is valued according to retail selling price (RSP) and includes any applicable taxes. Any currency conversions used in the creation of this report have been calculated using constant 2013 annual average exchange rates.

The Polish OTC pharmaceuticals market had total revenues of $3,487.6m in 2013, representing a compound annual growth rate (CAGR) of 6.6% between 2009 and 2013.

The traditional medicines segment was the market's most lucrative in 2013, with total revenues of $773.3m, equivalent to 22.2% of the market's overall value.

The performance of the market is forecast to accelerate, with an anticipated CAGR of 10.6% for the five-year period 2013 – 2018, which is expected to drive the market to a value of $5,779.1m by the end of 2018.

Scope

Save time carrying out entry-level research by identifying the size, growth, and leading players in the otc pharmaceuticals market in Poland

Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the otc pharmaceuticals market in Poland

Leading company profiles reveal details of key otc pharmaceuticals market players’ global operations and financial performance

Add weight to presentations and pitches by understanding the future growth prospects of the Poland otc pharmaceuticals market with five year forecasts

Macroeconomic indicators provide insight into general trends within the Poland economy

Reasons to buy

What was the size of the Poland otc pharmaceuticals market by value in 2013?

What will be the size of the Poland otc pharmaceuticals market in 2018?

What factors are affecting the strength of competition in the Poland otc pharmaceuticals market?

How has the market performed over the last five years?

Companies mentioned

Aflofarm Farmacja Polska Sp. z o.o., GlaxoSmithKline Plc, Johnson & Johnson and USP Zdrowie Sp. z o.o.

Table of Contents

TABLE OF CONTENTS

Executive Summary 2

Market value 2

Market value forecast 2

Category segmentation 2

Geography segmentation 2

Market share 2

Market rivalry 2

Market Overview 7

Market definition 7

Market analysis 7

Market Data 8

Market value 8

Market Segmentation 9

Category segmentation 9

Geography segmentation 10

Market share 11

Market distribution 12

Market Outlook 13

Market value forecast 13

Five Forces Analysis 14

Summary 14

Buyer power 15

Supplier power 16

New entrants 17

Threat of substitutes 18

Degree of rivalry 19

Leading Companies 20

Aflofarm Farmacja Polska Sp. z o.o. 20

GlaxoSmithKline Plc 21

Johnson & Johnson 25

USP Zdrowie Sp. z o.o. 28

Macroeconomic Indicators 29

Country Data 29

Appendix 31

Methodology 31

Industry associations 32

Related MarketLine research 32

LIST OF TABLES

Table 1: Poland OTC pharmaceuticals market value: $ million, 200913 8

Table 2: Poland OTC pharmaceuticals market category segmentation: $ million, 2013 9

Table 3: Poland OTC pharmaceuticals market geography segmentation: $ million, 2013 10

Table 4: Poland OTC pharmaceuticals market share: % share, by value, 2013 11

Table 5: Poland OTC pharmaceuticals market distribution: % share, by value, 2013 12

Table 6: Poland OTC pharmaceuticals market value forecast: $ million, 201318 13

Table 7: Aflofarm Farmacja Polska Sp. z o.o.: key facts 20

Table 8: GlaxoSmithKline Plc: key facts 21

Table 9: GlaxoSmithKline Plc: key financials ($) 23

Table 10: GlaxoSmithKline Plc: key financials (£) 23

Table 11: GlaxoSmithKline Plc: key financial ratios 23

Table 12: Johnson & Johnson: key facts 25

Table 13: Johnson & Johnson: key financials ($) 26

Table 14: Johnson & Johnson: key financial ratios 26

Table 15: USP Zdrowie Sp. z o.o.: key facts 28

Table 16: Poland size of population (million), 200913 29

Table 17: Poland gdp (constant 2005 prices, $ billion), 200913 29

Table 18: Poland gdp (current prices, $ billion), 200913 29

Table 19: Poland inflation, 200913 30

Table 20: Poland consumer price index (absolute), 200913 30

Table 21: Poland exchange rate, 200913 30

LIST OF FIGURES

Figure 1: Poland OTC pharmaceuticals market value: $ million, 200913 8

Figure 2: Poland OTC pharmaceuticals market category segmentation: % share, by value, 2013 9

Figure 3: Poland OTC pharmaceuticals market geography segmentation: % share, by value, 2013 10

Figure 4: Poland OTC pharmaceuticals market share: % share, by value, 2013 11

Figure 5: Poland OTC pharmaceuticals market distribution: % share, by value, 2013 12

Figure 6: Poland OTC pharmaceuticals market value forecast: $ million, 201318 13

Figure 7: Forces driving competition in the OTC pharmaceuticals market in Poland, 2013 14

Figure 8: Drivers of buyer power in the OTC pharmaceuticals market in Poland, 2013 15

Figure 9: Drivers of supplier power in the OTC pharmaceuticals market in Poland, 2013 16

Figure 10: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in Poland, 2013 17

Figure 11: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in Poland, 2013 18

Figure 12: Drivers of degree of rivalry in the OTC pharmaceuticals market in Poland, 2013 19

Figure 13: GlaxoSmithKline Plc: revenues & profitability 24

Figure 14: GlaxoSmithKline Plc: assets & liabilities 24

Figure 15: Johnson & Johnson: revenues & profitability 26

Figure 16: Johnson & Johnson: assets & liabilities 27

List of Tables

NA

List of Figures

NA

    Pricing

Quick Buy
Add to basket Enquire before buying

Discounts available for multiple purchases.

reportstore@marketline.com
+44 20 7947 2960

Saved reports